NMPA Approves Mabwell’s 8MW0511 for Febrile Neutropenia Prevention
China’s National Medical Products Administration (NMPA) has approved Mabwell (Shanghai) Bioscience Co., Ltd’s (SHA: 688062)...
Product approvals
Hinova’s Deutenzalutamide Approved for Metastatic Prostate Cancer in China
Chengdu-based biotech Hinova Pharmaceuticals Inc. (SHA: 688302) announced that the New Drug Application (NDA) for...
Genor Biopharma Gains NMPA Approval for CDK4/6 Inhibitor Lerociclib in China
China’s Genor Biopharma Co., Ltd (HKG: 6998) announced that it has received marketing clearance from...
Amoytop Biotech Wins NMPA Approval for Weekly Inpegsomatropin in Pediatric Growth Deficiency
Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) announced that it has received marketing approval from...
Abbott Laboratories Receives FDA Approval for Tendyne TMVR System
US-based medical device giant Abbott Laboratories (NYSE: ABT) announced that it has received marketing approval...
BMS Gains European Approval for Opdivo Subcutaneous Formulation
Bristol-Myers Squibb (BMS; NYSE: BMY) announced that the European Commission (EC) has granted approval to...
Novartis’ Fabhalta Approved for Previously Treated PNH Patients in China
The China unit of Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that the National Medical...
Sino Medical Sciences Technology’s AUCURA Flow-Diverting Stent Approved by NMPA
China-based Sino Medical Sciences Technology Inc. (SHA: 688108) announced that its holding subsidiary Neurovita has...
Yantai Dongcheng Pharma Gains NMPA Approval for Sodium Fluoride [18F]
China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has received marketing approval from the...
RemeGen’s Telitacicept Approved for Myasthenia Gravis in China
China-based pharmaceutical firm RemeGen (HKG: 9995) announced the third indication approval from the National Medical...
Salubris Pharma’s Xinchaotuo Gains NMPA Approval for Primary Hypertension
China-based Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) announced that it has received marketing approval...
Novartis’ Beovu Approved by NMPA for Diabetic Macular Edema Treatment
Swiss giant Novartis’ (NYSE: NVS) Beovu (brolucizumab) received approval from China’s National Medical Products Administration...
Junshi Biosciences’ Junshida Wins NMPA Approval for HeFH and Statin-Intolerant Patients
China’s Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced that it has received...
China’s NMPA Approves Lifetech’s Aortic Fenestration Stent System
China’s National Medical Products Administration (NMPA) recently approved an innovative aortic in-situ fenestration branch reconstruction...
Eisai’s Dayvigo Granted NMPA Approval for Insomnia Treatment
Japan-based Eisai Co., Ltd. (TYO: 4523) announced that it has received marketing approval from China’s...
Fosun Pharma’s HLX22 Granted Orphan Drug Designation by EU Commission
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that it has...
Bio-Thera Solutions’ BAT2206 Biosimilar of Stelara Gains FDA Approval
Guangzhou-based Bio-Thera Solutions Ltd. (SHA: 688177) announced that it has received Biologic License Application (BLA)...
Jemincare’s Irinotecan Liposome Injection Gains NMPA Approval for Pancreatic Cancer
China-based Jiangxi Jemincare Group announced that it has received marketing approval from the National Medical...
GSK’s Blenrep Recommended for EU Approval in Multiple Myeloma
UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced that its Blenrep (belantamab mafodotin) has been...
Grand Pharma’s GPN01768 Approved in Macau for Demodectic Blepharitis
Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced that its New Drug Application (NDA) for...